Search

Displaying results 151 - 160 of 332 in total
  1. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for

  2. Drug

    MB-107

    go.drugbank.com/drugs/DB18566
    Experimental

    MB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.

  3. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antib...

  4. Drug

    KT-A261

    go.drugbank.com/drugs/DB19317
    Experimental

    KT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.

  5. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells.

  6. Drug

    Sodium fluoride

    go.drugbank.com/drugs/DB09325
    ApprovedInvestigational

    Sodium fluoride is an inorganic chemical compound that is a source of the fluoride ion in many applications, including dental care and radiographic imaging when it is used as Fluoride ion F-18. Sodium fluoride's benefits on dental health...

    Products: Crest 3D White Advanced Express White
  7. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.

  8. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.

  9. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

  10. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.